Search News

Graco Inc. is a dividend growth stock with a 28-year streak, robust safety metrics, and no long-term debt. GGG's diversified niche product portfolio and recurring consumables revenue create a wide moat and consistent organic growth. Despite recent earnings misses and end-market weakness, GGG maintains strong cash flow, conservative payout ratios, and prudent capital allocation.

Pantheon Resources PLC (AIM:PANR, OTCQX:PTHRF) told investors it has paused testing operations at its Dubhe-1 well, in the Aphun project area, on Alaska's North Slope. The decision follows nearly two months of flowback activity, during which 100,000 barrels of water, 20 million cubic feet of gas and 100 barrels of oil were produced.

Ariana Resources PLC (AIM:AAU, ASX:AA2) has struck a binding deal with a Chinese mining services group that will inject an initial A$8 million of fresh cash into the company and fund key technical work on its Dokwe gold project in Zimbabwe. The AIM-quoted miner said the agreement marks an important step towards completing a full feasibility study at Dokwe, which it owns outright, and brings a strategic partner onto the register.

Nvidia is rated a strong buy, driven by its dominant AI infrastructure position and accelerating GPU architectures amid the end of Moore's Law. NVDA's revenue momentum is underpinned by a $0.5 trillion Blackwell/Rubin pipeline, robust hyperscaler demand, and a projected 40% long-term CAGR. Key risks include China export controls, power constraints, customer concentration, and potential re-rating if open-source AI or custom silicon erode demand.

Baidu's Apollo Go will begin robotaxi trials in the U.K. with Uber and with Lyft in 2026.

TOKYO--(BUSINESS WIRE)---- $INCY--Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for Relapsed/Refractory Follicular Lymphoma.

TOKYO--(BUSINESS WIRE)---- $INCY--Incyte Japan Announces Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer.

The pharmaceutical company said its ceralasertib combination didn't meet the primary goal of a late-stage clinical trial for advanced lung cancer.